Allysta Pharmaceuticals

Executive Summary

Allysta Pharmaceuticals is a private, clinical-stage biopharmaceutical company based in San Diego, CA, developing first-in-class therapeutic peptides for rare diseases with high unmet medical needs. Founded in 2016, the company is venture-backed and currently advancing its lead program, ALY-101, for Duchenne muscular dystrophy (DMD) and other fibrosing diseases. ALY-101 targets a novel mechanism to address muscle degeneration and fibrosis, and has entered Phase 1 clinical trials. The company's pipeline also includes preclinical candidates for additional rare fibrotic conditions, leveraging its proprietary peptide discovery platform. With a focused R&D strategy and experienced management team, Allysta aims to address significant gaps in current treatment options for patients with severe, life-limiting diseases. Allysta's near-term value inflection points center on the progression of ALY-101 through Phase 1, with initial safety and biomarker data expected in the second half of 2026. The company may also seek to expand its pipeline by advancing a second candidate into the clinic or securing strategic partnerships to support development and manufacturing. Given its early-stage profile and reliance on external financing, success depends on favorable clinical data and capital markets conditions. The company's novel approach to fibrosis and muscle disease offers a differentiated investment opportunity, albeit with inherent clinical and regulatory risks typical of Phase 1 biotech companies.

Upcoming Catalysts (preview)

• H2 2026Phase 1 Safety and Biomarker Data for ALY-101 in DMD60% success
• 2027IND Filing for Second Peptide Candidate in Fibrosing Disease40% success
• H2 2026Series B or Partnership Financing Announcement50% success